A soy glycinin derived octapeptide protects against MCD diet induced non-alcoholic fatty liver disease in mice  

作　　者：Peng Ma Rongrong Huang Yu Ou 

机构地区：[1]School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China

出　　处：《Food Science and Human Wellness》2022年第6期1544-1554,共11页食品科学与人类健康（英文）

基　　金：funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)。

摘　　要：Soy glycinin derived octapeptide(SGP8)is a peptide obtained from degradation of the soy glycinin,whose amino acid sequence is IAVPGEVA.To determine the effect of SGP8 on non-alcoholic fatty liver disease(NAFLD),steatosis Hep G2 cells were induced by 1 mmol/L free fatty acid(FFA)and C57 BL/6 J mice were fed with methionine-choline defi cient(MCD)diet for 3 weeks to establish NAFLD model.The results of oil red O staining and total cholesterol(TC)/triglyceride(TG)contents showed that SGP8 could signifi cantly reduce the lipid content of steatosis Hep G2 cells.In vivo,SGP8 lowered plasma alanine aminotransferase(ALT)and low density lipoprotein(LDL)content,normalized hepatic superoxide dismutase(SOD)and malondialdehyde(MDA)production,and reduced the severity of liver infl ammation.The results of Western blotting showed that SGP8 increased expression of Sirtuin-1(SIRT1)and phosphorylation level of AMP activated protein kinase(AMPK)in hepatocytes.Through activation of SIRT1/AMPK pathway,SGP8 downregulated the expression of sterol regulatory element binding protein 1 c(SREBP-1 c)and its target genes ACC and FAS expression levels,and increased the phosphorylation level of acetyl Co A carboxylase(ACC).Furthermore,SGP8 also upregulated the expression of transcription factor peroxisome proliferator activated receptorα(PPARα),which was regulated by SIRT1/AMPK pathway,and its target gene CPT1 level.In conclusion,SGP8 might improve NAFLD by activating the SIRT1/AMPK pathway.Our data suggest that SGP8 may act as a novel and potent therapeutic agent against NAFLD.

关 键 词：Soy glycinin derived octapeptide(SGP8) Non-alcoholic fatty liver disease(NAFLD) HepG2 cells Methionine-choline deficient(MCD) SIRT1/AMPK pathway 

分 类 号：R575.5[医药卫生—消化系统] TQ460.1[医药卫生—内科学]